Video

The Responsibility of Strong MS Treatment and Children Patients

Author(s):

Brenda Banwell, MD, FAAP, FRCPC, Children's Hospital of Philadelphia's Neurology Division chief, talks about the cruciality of early diagnosing in pediatric multiple sclerosis patients, and how their best outcome is just being able to live a normal, everyday life.

Multiple sclerosis (MS) in pediatric patients is almost always relapsing, and pediatric relapse rates have shown to be greater than that of adult patients.

That, along with the day-to-day livelihood of a child, makes an early diagnosis and treatment of pediatric MS crucial, Brenda Banwell, MD, FAAP, FRCPC, said.

Banwell, Children's Hospital of Philadelphia's Neurology Division chief, discussed the trends of pediatric MS at the annual Consortium of Multiple Sclerosis Centers (CMSC) in New Orleans this week. Banwell discussed how currently-approved treatments for MS are responsive in children patients, indicating pediatric MS may be manageable on a inflammation level if treated early.

But as clinicians continue to seek out the biological machinations of the neurological disorder — while quickly progressing the strength of treatment — Banwell advised caution to doctors treating pediatric MS.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.